all report title image
  • Published On : Jul 2022
  • Code : CMI1804
  • Industry : Pharmaceutical
  • Pages : 199
  • Formats :

Naloxone is a drug that effectively reverses an opioid overdose. It is an antagonist to opioids. This indicates that it binds to opioid receptors, where it blocks and reverses the effects of other opioids. If someone's respiration has slowed down or halted due to an opioid overdose, naloxone can swiftly get them back to normal breathing.

However, naloxone has no impact on people who do not have opioids in their system, and it is not used to treat opioid use disorder. Opioids include heroin, fentanyl, oxycodone (OxyContin), hydrocodone (Vicodin), codeine, and morphine.

Global Naloxone Market- Impact of Coronavirus (Covid-19) Pandemic

Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Dashboard by the World Health Organization, over 545 million cases and 6.33 million deaths due to coronavirus disease (COVID-19) were reported till July 01, 2022, across the globe.

Impact of COVID-19 on Demand and Supply of Naloxone

  • The COVID-19 pandemic and lockdown in various countries across the globe have impacted the financial status of businesses across all sectors including private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. The COVID-19 pandemic has affected the economy of various regions across the globe in three main ways; by directly affecting the production and demand of healthcare products; by creating disruptions in distribution channels; and by affecting the companies and various markets financially. Several countries such as Thailand, Indonesia, and Singapore are facing problems with regards to transportation and distribution of healthcare products.
  • There was a strong impact on Naloxone market during COVID-19 pandemic, owing to decreasing number in its filled prescriptions.For instance, according to an article published in the Healio Journal in May 2021, there was a significant drop in filled naloxone prescriptions that was greater than the drop in filled opioid prescriptions and any other drug during the COVID-19 pandemic.
  • The global naloxone market is estimated to be valued at US$ 1,118.3 Mn in 2022, and is expected to exhibit a CAGR of 10.4% over the forecast period (2022-2030).

Figure 1: Global Naloxone Market Share (%) Analysis, By Strength, 2022

Naloxone  | Coherent Market Insights

Increasing dependency on drugs and opioids overdose is expected to drive growth of the global naloxone market over the forecast period.

For instance, according to the data published by World Health Organization in August 2021, around 0.5 million deaths are caused by drug use, with more than 30% of these deaths attributable to overdose and more than 70% of these deaths caused due to opioids worldwide. Moreover, according to the data published by the Centers for Disease Control and Prevention, 2021, the national public health agency of the U.S. in November 2021, around 100,306 drug overdose deaths were reported in U.S. during 12-month period ending in April 2021.

CMI table icon

Naloxone Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 1,118.3 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 10.4% 2030 Value Projection: US$ 2,460.2 Mn
Geographies covered :
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Strength: 2.0 mg/0.1 ml and 4.0 mg/ml, 1 mg/ml 0.4 mg/ml, Others
  • By Route of Administration: Intranasal, Intramuscular/Subcutaneous, Intravenous
  • By Distribution Channel: Hospitals (Public Hospitals, Private Hospitals), Clinics (Including Addiction Clinics), Retail Pharmacies, Emergency Medical, Services (EMS), Military Facilities,Miscellaneous Facilities,Online Pharmacies, Others (long-term care facilities, etc.)
Companies covered :

Viatris Inc., Opiant Pharmaceuticals, Akorn Operating Company LLC, Pfizer, Inc., Novartis AG, Indivior Plc., Emergent BioSolutions Inc., Amphastar Pharmaceuticals, Inc., Kern Pharma, S.L., Hikma Pharmaceuticals PLC, Mundipharma International Limited, and Kaleo, Inc.

Growth Drivers:
  • Increasing dependency on opioids
  • Increasing government initiatives for naloxone distribution
  • Increasing product launches or approvals by market players
Restraints & Challenges:
  • Low awareness and accessibility of Naloxone in emerging economies

Increasing Initiatives by Government and Private Organizations

Various naloxone manufacturers, private organizations, and government organizations are focusing on initiatives to reduce death rate related to opioids overdose by increasing access to products such as naloxone for the population. For instance, on March 3, 2022, the Delaware Department of Health and Social Services’ Division of Substance Abuse and Mental Health (DSAMH) announced about hosting free monthly naloxone access training for all members of the Delaware state. This training will include learning about recognizing and responding to an opioid overdose.

Global Naloxone Market- Restraint

Low awareness and accessibility of naloxone is expected to be major restrain for the market growth. For instance, according to data published by the European Monitoring Centre for Drugs and Drug Addiction in 2016, naloxone was available in only a third of EU (European Union) member states, despite it being listed as an essential medicine by the WHO. Hence, low accessibility of naloxone among such key regions is expected to be a major restrain for the market growth.

Global Naloxone Market – Regional Analysis

On the basis of region, the global naloxone market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to exhibit lucrative growth opportunities for the naloxone market, owing to increasing product launches or approvals by market players in U.S. For instance, in April 2021, Hikma Pharmaceuticals PLC (Hikma), a multinational pharmaceutical company, announced the approval of KLOXXADOTM (naloxone hydrochloride) nasal spray 8mg, by the U.S. Food and Drug Administration (FDA) for the emergency treatment of known or suspected opioid overdose, as exhibited by respiratory and/or central nervous system depression, for adult and pediatric patients.  

Moreover, Asia Pacific is expected to witness significant growth in the near future, owing to increasing government initiatives for naloxone distribution in the region. For instance, in February 2022, the Australian Government invested US$ 3.9 million in the ‘take home naloxone pilot’, a program to make naloxone available free to people who may experience, or witness, an opioid overdose.

 Figure 2: Global Naloxone Market Value (US$ Mn), by Region, 2022

Naloxone  | Coherent Market Insights

Global Naloxone Market – Competitive Landscape

Major players operating in the global naloxone market include Viatris Inc., Opiant Pharmaceuticals, Akorn Operating Company LLC, Pfizer, Inc., Novartis AG, Indivior Plc., Emergent BioSolutions Inc., Amphastar Pharmaceuticals, Inc., Kern Pharma, S.L., Hikma Pharmaceuticals PLC, Mundipharma International Limited, and Kaleo, Inc.

Naloxone is available in two U.S. Food and Drug Administration (FDA) approved forms: injection and nasal spray. It is crucial to be educated on how and when to administer naloxone regardless of the type of medication being utilized. Those who are physically dependent on opioids may experience withdrawal symptoms minutes after receiving naloxone. Headaches, variations in blood pressure, a rapid heartbeat, sweating, nausea, vomiting, and tremors are examples of withdrawal symptoms. Although uncomfortable, this normally does not pose a life-threatening threat.

Market Dynamics

High prevalence of opioid overdose and increasing opioid crises in the U.S. are expected to fuel demand for naloxone in the region and thus, driving the market growth during the forecast period. For instance, according to the data published by the National Institute on Drug Abuse, 2021, U.S. federal government research institute, in the year 2019, about 50,000 people died from opioid-involved overdoses in the U.S. The addiction and misuse of opioids including heroin, synthetic opioids (fentanyl), and prescription pain relievers is a severe national crisis which affects social & economic welfare, and public health.

Market players are focused on product launches and approvals, which is expected to drive growth of the global naloxone market over the forecast period. For instance, in February 2019, Indivior Inc., a U.S. affiliate of Indivior Plc., launched an authorized generic version of SUBOXONE (naloxone and buprenorphine) sublingual film in the U.S. This authorized generic is being distributed and marketed on Indivior’s behalf by Sandoz Inc., one of the leading providers of generic pharmaceuticals and biosimilars.

Increasing initiatives by governments related to use and distribution of naloxone is expected to fuel growth of the global naloxone market. For instance, in February 2018, Loyola Medicine and the U.S. based Cook County Department of Homeland Security and Emergency Management collaborated, where Loyola Medicine trained police to use Narcan in the case of opioids overdose. Moreover, in 2017, Ontario government provided naloxone kits to police and fire departments in Ontario, Canada, to manage emergency case of opioid overdose. Government of Canada offered naloxone kits to all 61 police services and 447 fire departments in the Ontario province.

Key features of the study:

  • This report provides an in-depth analysis of the global naloxone market , provides market size (US$ Million), and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global naloxone market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Viatris Inc., Opiant Pharmaceuticals, Akorn Operating Company LLC, Pfizer, Inc., Novartis AG, Indivior Plc., Emergent BioSolutions Inc., Amphastar Pharmaceuticals, Inc., Kern Pharma, S.L., Hikma Pharmaceuticals PLC, Mundipharma International Limited, and Kaleo, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global naloxone market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global naloxone market

Detailed Segmentation:

  • Global Naloxone Market, By Strength:
    • 0 mg/0.1 ml and 4.0 mg/ml
    • 1 mg/ml
    • 4 mg/ml
    • Others (Naloxone 2mg/2 ml vial, etc.)
  • Global Naloxone Market, By Route of Administration:
    • Intranasal
    • Intramuscular/Subcutaneous
    • Intravenous
  • Global Naloxone Market, By Distribution Channel:
    • Hospitals
      • Public Hospitals
      • Private Hospitals
    • Clinics (Including Addiction Clinics)
    • Retail Pharmacies
    • Emergency Medical Services (EMS)
    • Military Facilities
    • Miscellaneous Facilities
    • Online Pharmacies
    • Others (long-term care facilities, etc.)
  • Global Naloxone Market , By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Viatris Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Opiant Pharmaceuticals
    • Akorn Operating Company LLC
    • Pfizer, Inc.
    • Novartis AG
    • Indivior Plc.
    • Emergent BioSolutions Inc.
    • Amphastar Pharmaceuticals, Inc.
    • Kern Pharma, S.L.
    • Hikma Pharmaceuticals PLC
    • Mundipharma International Limited
    • Kaleo, Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

Global naloxone market is expected to exhibit a CAGR of 10.4% during the forecast period (2022-2030).
The market is estimated to be valued at US$ 1,118.3 Mn in 2022.
Viatris Inc., Opiant Pharmaceuticals, Akorn Operating Company LLC, Pfizer, Inc., Novartis AG, Indivior Plc., Emergent BioSolutions Inc., Amphastar Pharmaceuticals, Inc., Kern Pharma, S.L., Hikma Pharmaceuticals PLC, Mundipharma International Limited, and Kaleo, Inc. are some of the prominent players operating in the market.
The market is expected to be valued at US$ 2,460.2 Mn in 2030.
North America is the prominent region in the market.
Increasing dependency on opioids, increasing government initiatives for naloxone distribution, and increasing product launches or approvals by market players are some of the driving factors, which are expected to drive growth of the market.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo